Literature DB >> 10850863

Allelic losses in neurofibromatosis 2-associated meningiomas.

K Lamszus1, F Vahldiek, V F Mautner, C Schichor, J Tonn, D Stavrou, R Fillbrandt, M Westphal, L Kluwe.   

Abstract

More than 50% of patients with neurofibromatosis 2 (NF2) develop meningiomas. Recently, a higher proliferative activity, more mitotic figures, and greater nuclear pleomorphism have been described for NF2-associated meningiomas compared with sporadic ones. To analyze whether such histological differences could reflect underlying genetic differences, we examined 30 meningiomas from 22 NF2 patients for allelic losses on those chromosome arms that are frequently affected by deletions in sporadic meningiomas. In addition, we assessed the proliferative activity of the tumors and studied NF2 germline mutations. Twenty-three meningiomas corresponded to WHO grade I (10 fibrous, 6 psammomatous, 4 transitional, 3 meningothelial) and 7 to WHO grade II. The average MIB-1 index was 1.60 +/- 0.85 (WHO grade I: 1.41 +/- 0.80, WHO grade II: 2.13 +/- 0.82). When compared with several published studies of sporadic meningiomas, the MIB-1 index in NF2-associated meningiomas was not higher. Loss of heterozygosity (LOH) flanking or within the NF2 locus at 22q12 was detected in 100% of the tumors. LOH on 1p was the second most frequent abnormality (40%), followed by losses on 10q (27%), 6q and 14q (24%), 18q (23%), and 9p (17%). LOH on 19q and 17p, which is not commonly seen in sporadic meningiomas, was also only rarely detected in NF2-associated meningiomas. NF2 gene mutations were detected in 8 of 15 patients analyzed and were located in exons 2, 5, 6, 7, and 8. We conclude that sporadic and NF2-associated meningiomas share a common spectrum and frequency of allelic deletions as well as, in contrast to previous observations, a similar proliferative activity.

Entities:  

Mesh:

Year:  2000        PMID: 10850863     DOI: 10.1093/jnen/59.6.504

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  11 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

Review 2.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

3.  Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.

Authors:  Stéphane Goutagny; Alpha Boubacar Bah; Dominique Henin; Béatrice Parfait; Alexis Bozorg Grayeli; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

4.  Meningiomas.

Authors:  Jeffrey Raizer
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

5.  Multiple meningiomas: differential involvement of the NF2 gene in children and adults.

Authors:  D G R Evans; C Watson; A King; A J Wallace; M E Baser
Journal:  J Med Genet       Date:  2005-01       Impact factor: 6.318

Review 6.  Meningiomas and neurofibromatosis.

Authors:  Stéphane Goutagny; Michel Kalamarides
Journal:  J Neurooncol       Date:  2010-08-17       Impact factor: 4.130

7.  Meningiomas.

Authors:  Sean Grimm; Jeffrey J Raizer
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

8.  Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker.

Authors:  Paola E Leone; Marta Mendiola; Javier Alonso; César Paz-y-Miño; Angel Pestaña
Journal:  BMC Cancer       Date:  2003-03-04       Impact factor: 4.430

9.  Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.

Authors:  Michel Kalamarides; Anat O Stemmer-Rachamimov; Masaya Takahashi; Zhi-Yan Han; Fabrice Chareyre; Michiko Niwa-Kawakita; Peter M Black; Rona S Carroll; Marco Giovannini
Journal:  Brain Pathol       Date:  2007-10-09       Impact factor: 6.508

Review 10.  Peroxiredoxin 1 - an antioxidant enzyme in cancer.

Authors:  Chenbo Ding; Xiaobo Fan; Guoqiu Wu
Journal:  J Cell Mol Med       Date:  2016-09-21       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.